ADS-051 is under clinical development by Adiso Therapeutics and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADS-051’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADS-051 overview
BT-051 is under development for the treatment of ulcerative colitis. The drug candidate is a new chemical entity. It is administered by oral route. It acts by targeting Multidrug Resistance Associated Protein 2 (MRP2) and fMet-Leu-Phe Receptor (FPR1).
Adiso Therapeutics overview
Adiso Therapeutics (Adiso), formerly Artugen Therapeutics USA, is a clinical-stage biopharmaceutical company that develops novel medicines to treat inflammatory diseases. The company’s products pipeline includes ADS051, an oral gut-restricted modulator of neutrophil trafficking and activation used for the treatment of ulcerative colitis; and ADS032, a small molecule dual (NLRP3 and NLRP1) inflammasome inhibitor for the treatment of respiratory and dermal inflammation. Its partnering pipeline products include ADS024, an oral single-strain live biotherapeutic product for the treatment of ulcerative colitis and prevention of C. difficile recurrence. It works in collaboration with academics and institutions including the University College Cork, Ireland, the Hudson Institute of Medical Sciences Centre for Innate Immunity and Infectious Diseases in Australia, the University of Edinburgh Centre for Inflammation Research, the University of Massachusetts Chan Medical School and the APC Microbiome Institute. Adiso is headquartered in Concord, Massachusetts, the US.
For a complete picture of ADS-051’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
